Fate Therapeutics Inc FATE:NASDAQ

Last Price$19.89Cboe Real-Time Last Sale as of 2:23PM ET 6/20/19
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.10(0.50%)
Bid (Size)$19.86 (200)
Ask (Size)$19.91 (200)
Day Low / High$19.84 - 20.84
Volume410.5 K
 

View Biotechnology IndustryPeer Comparison as of 06/20/2019

 

Fate Therapeutics Inc ( NASDAQ )

Price: $19.89
Change: -0.10 (0.50%)
Volume: 410.5 K
2:23PM ET 6/20/2019
 
 

Alector Inc ( NASDAQ )

Price: $18.27
Change: -0.85 (4.45%)
Volume: 62.3 K
1:48PM ET 6/20/2019
 
 

Veracyte Inc ( NASDAQ )

Price: $28.08
Change: -0.25 (0.88%)
Volume: 279.9 K
2:24PM ET 6/20/2019
 
 

Aimmune Therapeutics Inc ( NASDAQ )

Price: $20.37
Change: +0.30 (1.49%)
Volume: 404.9 K
2:11PM ET 6/20/2019
 
 

Momenta Pharmaceuticals Inc ( NASDAQ )

Price: $12.82
Change: +0.18 (1.42%)
Volume: 352.2 K
2:25PM ET 6/20/2019
 

Read more news Recent News

Analyst Actions: Mizuho Securities Starts Fate Therapeutics at Buy, With $27 Price Target
10:01AM ET 6/13/2019 MT Newswires

Fate Therapeutics' (FATE) average rating among analysts is a buy, with an average price target of $21. Price: 16.87, Change: +0.33, Percent Change: +2.00...

Analyst Actions: Roth Capital Initiates Coverage on Fate Therapeutics With Neutral Rating and $20 PT
9:12AM ET 6/07/2019 MT Newswires

Fate Therapeutics' (FATE) average rating among analysts is a buy, with an average price target of $21. Price: 17.71, Change: -1.35, Percent Change: -7.08...

Analyst Actions: Guggenheim Starts Fate Therapeutics at Buy, With $25 Price Target
8:41AM ET 5/31/2019 MT Newswires

Fate Therapeutics' (FATE) average rating among analysts is a buy, with an average price target of $20. Price: 19.94, Change: -0.25, Percent Change: -1.24...

Fate Therapeutics Says First Patient Treated With Cancer Therapy Completes Initial Safety Assessment
8:28AM ET 4/02/2019 MT Newswires

Fate Therapeutics (FATE), a clinical-stage biopharmaceutical company, said pre-market Tuesday that the first patient treated with its cancer drug FT500...

Company Profile

Business DescriptionFate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA. View company web site for more details
Address3535 General Atomics Court
San Diego, California 92121
Phone+1.858.875.1800
Number of Employees104
Recent SEC Filing05/28/20194
President, Chief Executive Officer & DirectorJ. Scott Wolchko
Chief Scientific OfficerDaniel D. Shoemaker
Vice President-Clinical DevelopmentYu Waye Chu
Senior Vice President-Corporate DevelopmentJim Beitel

Company Highlights

Price Open$20.20
Previous Close$19.99
52 Week Range$8.64 - 20.84
Market Capitalization$1.3 B
Shares Outstanding65.2 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/05/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.23
Beta vs. S&P 500N/A
Revenue$4.7 M
Net Profit Margin-1,138.09%
Return on Equity-54.30%

Analyst Ratings as of 06/07/2019

Buy
8
Overweight
0
Hold
1
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset